Scientists discover prototype test to help in fighting deadly melanoma ANI | Updated: Feb 21, 2021 23:23 IST
Washington [US], February 21 (ANI): A team of scientists from Australia published a study in the journal Clinical Cancer Research that shows their new discovery of a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.
Australian researchers from QIMR Berghofer Medical Research Institute conducted the study. Details about the test and the research have been published on Monday (local time) in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.
Prototype test to help fight deadly melanoma newzealandstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newzealandstar.com Daily Mail and Mail on Sunday newspapers.
New prototype test determines benefit of immunotherapy against deadly metastasised melanoma aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
SINGAPORE (The Straits Times/ANN): The massive hack that hit Singtel recently was part of a wider global cyber breach that affected thousands of organisations worldwide.
Researchers develop new test to help fight deadly melanoma ANI | Updated: Feb 16, 2021 06:00 IST
Washington [US], February 16 (ANI): Researchers have developed a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.
Australian researchers from QIMR Berghofer Medical Research Institute conducted the study. Details about the test and the research have been published on Monday (local time) in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.